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doi:10.1016/j.pedneo.2010.12.008Background: The PalmLab glucometer is a newly designed plasma separation glucose oxidase
(GO)-based glucometer. Past studies have shown that the accuracy of GO-based glucometers
is compromised when measurements are taken in patients with high PO2 levels. We performed
a two-arm study comparing the fitness of the PalmLab blood glucometer with that of a standard
glucose analyzer in monitoring blood glucose levels in pediatric patients, especially when arte-
rial partial pressure of oxygen (PO2) was high.
Methods: In the first arm of the study, arterial blood samples from pediatric patients were
measured by the PalmLab blood glucometer and the YSI 2302 Plus Glucose/Lactate analyzer.
In the second arm of the study, venous blood samples from adult volunteers were spiked with
glucose water to prepare three different levels of glucose (65, 150, and 300 mg/dL) and then
oxygenated to six levels of PO2 (range, 40e400 mmHg). The biases of the PalmLab glucometer
were calculated.
Results: A total of 162 samples were collected in the first arm of the study. Results of linear
regression showed that the coefficient of determination (R2) between PalmLab glucometer
and standard glucose analyzer was 0.9864. Error grid analysis revealed that all the results weret of Pediatrics, Changhua Christian Hospital, Changhua, 135 Nanxiao St., Changhua City, ChangHua
, 107484@cch.org.tw (H.-Y. Chiu).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
GO-based glucometer monitoring in pediatric ICU 25within Zone A (clinically accurate estimate zone). The biases between the two systems were
low at different PO2 levels. In the second arm of the study, the results were also unaffected
by changes in PO2.
Conclusion: The PalmLab glucometer provides accurate results in samples with high PO2 and is
suitable for measuring arterial glucose levels in pediatric patients.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Daily bedside glucose monitoring is a routine practice in
pediatric intensive care units. Arterial lines are frequently
inserted in this group of patients, and arterial samples can
be drawn from these lines or from skin punctures for rapid
glucose testing. There are several glucose monitoring
systems available today, and these glucose meters can be
roughly classified into glucose dehydrogenase (GD)-based
system or glucose oxidase (GO)-based systems. The accu-
racy of traditional GO-based monitoring systems is affected
by high PO2 values, which limits their clinical use for arterial
blood samples.1,2 GO-based test strips use GO to catalyze
the oxidation reaction that changes glucose into gluconic
acid. The levels of glucose will be detected by the number
of electrons that connects to an electrode, produced by
several sequences of oxidation and reduction reactions.
Oxygen competes with electron mediators (reduced flavin
adenine dinucleotide) produced after the above-mentioned
reactions. No electrons are produced in the oxygen side of
the reaction. It, therefore, follows that lower blood glucose
readings will be obtained in blood samples with higher PO2
values. The chemical reactions measured by GO- and GD-
based test strips are displayed below:
1. GD-based strips
Glucose þ GO=FAD/ gluconicacid þ GO=FADH2
GO=FADH2 þ ferricyanide/GO=FAD þ ferrocyanide
Ferrocyanide/ ferricyanide þ e
GO=FADH2 þ O2/GO=FAD þ H2O2
2. GD-based strips
Glucose þ GD=PQQ/ gluconicacid þ GD=PQQH2GD=PQQH2 þ ferricyanide/GD=PQQ þ ferrocyanide
Ferrocyanide/ ferricyanide þ e
where FADZ flavin adenine dinucleotide; FADH2Z reduced
flavin adenine dinucleotide; PQQZ pyrroloquinoline
quinone; PQQH2Z reduced pyrroloquinoline quinone.
The PalmLab blood glucose monitoring system is a GO-
based monitoring system manufactured by Sand County
Biotechnology Inc., Taiwan. It is equippedwith amicroporous
blood filtration layer. The PalmLab glucose test strip
is composed of two conductive electrodes covered with
a reaction chamber in the blood testing area. The reaction
chamber is composed of two layers: the microporous bloodfiltration layer and the reagent layer. When a drop of blood is
drawn into the reactive chamber, the blood cells are blocked
at microporous blood filtration layer from entering the
reagent layer. Therefore, glucose content is onlymeasured in
the plasma portion of the blood sample (Figure 1).
Pre-clinical and clinical trials have shown that the
PalmLab glucometer can measure glucose concentrations in
the range of 10e600 mg/dL (0.6e33.3 mmol/L). It has been
shown to perform well within an operating temperature
range of 10e40C in both venous and capillary samples of
adults. It takes only 0.1 mL on each glucose monitoring.3 In
this two-arm study, we evaluated the accuracy of the
PalmLab glucometer in measuring glucose concentrations in
arterial samples with high PO2 levels in pediatric patients in
critical care units.
2. Materials and Methods
The two-arm study was performed from February 10, 2009
to February 27, 2009 at the Chunghua Christian Hospital,
Taiwan.
2.1. First-arm study patient samples and methods
In the first arm, arterial samples were collected from
arterial lines or arterial punctures from 104 patients in the
neonatal intensive care unit (age range, 0e1 month) and
from 58 patients in the pediatric intensive care unit (age
range, 0e17 years). All blood samples were collected in
conjunction with existing physician’s orders for laboratory
testing and tested immediately for hematocrits (Hct) and
PO2 using a Stat Profile Blood Gas Analyzer (Nova Biomed-
ical, MA, USA). Glucose concentration in an aliquot of each
whole blood sample was measured by the PalmLab blood
glucose monitoring system and by a reference instrument,
the YSI 2302 Plus Glucose/Lactate analyzer (Yellow Spring
Instruments, OH, USA), an instrument that has been shown
not to be affected by the blood oxygen effect.4 The study
protocol was approved by the institutional review board of
the Chunghua Christian Hospital, and informed consent was
obtained from the parents of each patient before blood
sampling.
According to ISO 15197 guideline for in vitro glucose
monitoring systems, 95% of individual glucose rapid test
results shall fall within 15 mg/dL of the standard manufac-
turer’s measurement procedure at glucose concentrations
less than 75 mg/dL and within 20% of glucose concentrations
greater than or equal to 75 mg/dL.5 We, therefore, plotted
a bias graph to show the effect of PO2 on glucose monitoring.
Figure 1 Structure of the multilayer element of PalmLab
glucose test strip for quantifying plasma glucose from the
whole blood sample.
26 M.-S. Lee et alBiases of the results from the PalmLab system were calcu-
lated using the following formulas:
Bias ðmg=dLÞZðYSI result PalmLab resultÞ;
at glucose level 75mg=dL
Bias ð%ÞZfðYSI result PalmLab resultÞ=ðYSI resultÞg
 100%; at glucose level> 75mg=dL
2.2. Second-arm study patient samples and
methods
In the second arm of the study, blood samples from healthy
adult volunteers who had not taken any medication before
blood donation were analyzed to determine whether high
blood PO2 levels would affect the glucose readings from the
PalmLab system. Samples were collected in lithium heparin
Vacutainer tubes (Becton-Dickson, Rutherford, NJ, USA)
and mixed well by inverting 20 times. The heparinized
blood was kept at room temperature overnight for glycol-
ysis to glucose level of 0 mg/dL. Glucose was then added to
venous samples to prepare three different levels of
glucose: low (65 mg/dL), medium (150 mg/dL), and high
(300 mg/dL). The spiked samples with different glucose
levels were then oxygenated with a Piston-type regulator
and flow meter (Genstar Technologies Inc., Chino, CA, USA)
to desired PO2 levels. Six levels of oxygenated blood
samples were prepared: 40, 80, 120, 240, 320, and
400 mmHg. The oxygen content of each prepared blood
sample was verified by a blood gas analyzer (Stat Profile,
Nova Biomedical, Waltham, MA, USA). Blood samples with
different glucose and oxygen levels were measured three
times by the PalmLab glucometer. The mean values of
the results from the three readings were calculated and
compared with those measured by the oxygen-insensitive
YSI reference instrument. The oxygen effect was evaluatedbased on the mean difference (instrument bias) in glucose
value between the PalmLab glucose meter and the YSI
reference instrument. The biases were recalculated
according to ISO 15197 guideline.
2.3. Statistical analysis
In the first arm of the study, the correlation between the
PalmLab results and the reference results was analyzed
using least-squares linear regression analysis. The clinical
accuracy of the blood glucose monitors in estimating
glucose concentration was examined using the error grid
analysis proposed by Clark et al.6,7 The glucose concen-
trations measured by the PalmLab system were plotted
against the reference values within a grid divided into five
zones.
Results in zone A are clinically accurate estimates. The
values in this zone deviate from the reference by less than
20% at glucose concentrations greater than or equal to
75 mg/dL and less than 15 mg/dL when the glucose
concentrations are less than 75 mg/dL. Zone B is a region of
acceptable estimates in which the estimate values deviate
by greater than 20% at glucose concentrations greater than
or equal to 75 mg/dL. Zone C results indicate over-
correcting of acceptable blood glucose levels, and Zone D
results are potentially dangerous and represent failure to
detect and treat glucose levels outside the desired target
range. Finally, data in Zone E would lead to treatment that
is the opposite of what is appropriate.8,9
3. Results
The characteristics of the 162 patients (104 neonates and
58 children) from whom blood samples were taken are lis-
ted in Table 1. The blood glucose concentrations ranged
from 43.0 mg/dL to 458 mg/dL, and the PO2 levels ranged
from 29.5 mmHg to 341.7 mmHg. Linear regression analysis
(Figure 2) showed good correlation (coefficient of deter-
mination, R2Z 0.986) between the results obtained from
the PalmLab glucometer and those obtained from the
reference instrument (YSI 2302 Plus Glucose/Lactate
analyzer).
The clinical accuracy was analyzed according to the
methodology suggested by ISO 15197 guideline. In the 18
patients with glucose levels less than or equal to 75 mg/dL
(4.2 mmol/L), we found that glucose concentrations fell
within 15 mg/dL (0.83 mmol/L) of the reference range; the
concentrations in 12 (66.7%) of the 18 patients fell within
5 mg/dL of the reference range; and the levels in 6
(33.3%) of the 18 patients were within 10 mg/dL of the
reference range (Table 2). In the 142 patients with glucose
concentrations greater than 75 mg/dL, the levels were
within 20% of the reference range (Table 3).
The clinical significance of errors in glucose determina-
tions was analyzed using the error grid analysis method
proposed by Clarke et al.6 A scatter-plot of PalmLab results
(y-axis) versus YSI Stat Plus results (x-axis) was overlaid
with an error grid consisting of a line of identity (yZ x) and
zones of clinical significance. Each point on the scatter-plot
fell into one of these zones. The error-grid analysis showed
that all measured glucose results were within the clinically
Table 1 Demographics of participants
Demographic characteristic
No. of patients 162
PICU 104
NICU 58
Gender
Female/male 92/70
Age (yr)
Mean 7.8
Range 0e17.0
SD 4.8
Glucose (mg/dL)
Mean 127.8
Range 44.2e599.0
SD 73.6
PO2 (torr; mmHg)
Mean 90.9
Range 29.5e341.7
SD 36.0
PICUZ pediatric intensive care unit; NICUZ neonatal intensive
care unit; SDZ standard deviation
Table 2 System accuracy results for glucose concentra-
tion  75 mg/dL (4.2 mmol/L)
Within  5 mg/dL (within  0.28 mmol/L) 12/18 (66.7%)
Within 10 mg/dL (within  0.56 mmol/L) 18/18 (100%)
Within 15 mg/dL (within  0.83 mmol/L) 18/18 (100%)
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inferior zones, such as Zone B or Zone C (Figure 3).
Blood gas analysis was performed at the time of blood
sampling in order to analyze the possible impact that PO2
had on glucose measurements. There was a wide variation
in PO2 levels among the 162 patients (range, 29.5e
341.7 mmHg). The bias plot for the PalmLab system (rela-
tive to the YSI reference method) shows that the test
results were not significantly affected by the PO2 in arterial
blood samples (Figure 4). The biases in the group of
patients with blood glucose levels less than 75 mg/dL
ranged from 9.4 to 6.7 mg/dL, and those in the group of
patients with glucose levels greater than 75 mg/dL rangedFigure 2 Pearson’s correlation and simple linear regression
between PalmLab results and reference results. (nZ 162;
p< 0.001; and 95% confidence interval of regression coefficient
is 0.970e1.006).from 12.7% to 17.0%. The biases conformed to the
requirements of ISO 15197 guideline.
Figure 5 shows the results of the second arm of the study.
As seen in blue line, changes in PO2 (range, 39e419 mmHg)
in blood samples with low glucose concentrations (65 mg/
dL) affected the accuracy of PalmLab blood glucose moni-
toring system within acceptable range (bias range, 4.8 to
0.2 mg/dL). Similarly, as seen in red and green lines,
changes in PO2 (range, 40e406 mmHg) in blood samples with
moderate (150 mg/dL) and high (300 mg/dL) glucose
concentrations did not affect the accuracy of the gluc-
ometer markedly. The biases in both cases were within 10%
(range, 6.4% to 2.6% and 7.9% to 2.9%, respectively).
4. Discussion
Studies have shown that the accuracy of GO-based gluc-
ometers is compromised when measurements are taken in
patients with high PO2 levels.
10,11 This problem is especially
relevant in neonates because fetal hemoglobin has higher
O2 affinity than adult hemoglobin. In this two-arm clinical
study, we found that the results obtained from the newly
designed plasma separation bedside PalmLab (GO-based)
blood glucose monitoring system correlated well with those
obtained from a standard laboratory blood glucose system
at high PO2 levels in neonates and pediatric patients in
critical care units. Although in Figure 5 we can still find
higher bias at high PO2 samples, all test results were within
the acceptable range defined by ISO 15197 guideline. At
37C, 1 mL of plasma contains 0.00003 mL O2/mmHg PO2,
and each gram of hemoglobin is capable of combining with
about 1.34 mL of oxygen under the same conditions. In
a patient with a hemoglobin level of 13 g/dL, the plasma
oxygen content is less than 2% of the total blood oxygen
content.12 Such a little amount of oxygen in the chemical
reaction of a GO-based glucose monitoring system may not
affect the result markedly and can explain why the Palm-
Lab glucometer performs well when measuring glucose
content in high PO2 samples.
Some of the commercially available glucose test strips
contain glucose dehydrogenase-pyrroquinoline quinone (GD-
PQQ). Studies have shown that the results obtained from
those types of test strips are not affected by oxygen because
oxygen does not compete with electromediators for PQQH2
(reduced form of pyrroloquinoline quinone), and are notTable 3 System accuracy results for glucose concentra-
tion of greater than 75 mg/dL (4.2 mmol/L)
Within  5% 71/142 (50.0%)
Within  10% 131/142 (92.3%)
Within  15% 141/142 (99.2%)
Within  20% 142/142 (100%)
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Figure 3 The error grid analysis shows that all measured
glucose results are within the accurate estimate zone (Zone A).
Figure 5 Results of low (65 mg/dL), medium (150 mg/dL),
and high (300 mg/dL) glucose levels are shown in blue, red, and
green lines, respectively. Changes in PO2 (35e425 mmHg) did
not affect the accuracy of results; all the biases were within
10 mg/dL when glucose level is less than or equal to 75 mg/dL
and within 10% when glucose level is greater than 75 mg/dL.
(For interpretation of the references to color in this figure
legend, the reader is referred to the online version of this
article).
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13,14 However, icodextrin, a glucose
polymer widely used in continuous ambulatory peritoneal
dialysis (Extraneal) interferes with the accuracy of GD-PQQ-
based glucose meters. Icodextrin enters the systemic
circulation during peritoneal dialysis and is hydrolyzed by
amylase to maltose or other oligosaccharides. GD-PQQ-
based glucometers cannot distinguish maltose from glucose.
Therefore, pseudohyperglycemia may lead to administra-
tion of insulin, which may lead to hypoglycemia.15 In
patients receiving maltose, icodextrin, galactose, or xylose,
clinicians must avoid using GD-PQQ-based glucose meters
and should only use glucose dehydrogenase nicotinamide
adenine dinucleotide (GDH-NAD)-, GO-, or glucose hexoki-
nase-based glucometers.16,17 Galactosemia in pediatric
patients can produce inaccurate readings when glucose
levels are measured with GD-PQQ-based handheld point-of-
care systems. Maltose-, galactose-, and xylose-containing
intravenous immunoglobulin products can cause the same
problem.18
In our study, only two patients in the pediatric intensive
care unit had a PO2 greater than 200 mmHg in the first armFigure 4 The plot of biases for PalmLab system (relative to
the YSI reference method) at different PO2 levels. The biases in
the group of patients with blood glucose levels of less than
75 mg/dL ranged from 9.4 to 6.7 mg/dL and those in the
group of patients with glucose levels of greater than 75 mg/dL
ranged from 12.7% to 17.0%. The biases conform to the
requirements of ISO 15197 guideline.of the study, although the two rapid glucose test results
conformed with the ISO 15197 guideline definition. To
improve this limitation, we oxygenated blood samples from
adult volunteers in the second arm of the study, and
showed that the PalmLab provided accurate results in
samples with a PO2 of 400 mmHg.
Another benefit of the PalmLab system is that it directly
measures plasma glucose levels. Most handheld glucometers
measure whole blood glucose levels and present plasma-
equivalent values using a conversion factor of 1.11 (plas-
maZwhole blood 1.11). In polycythemic patients,
however, this conversion factor can lead to false-positive low
glucose level readings.19e21 Therefore it is conceivable that
neonates who have relatively high hematocrits will have
more accurate rapid test results when blood separation test
strips are used. Further study is required to check the clinical
accuracy of the PalmLab system in polycythemic newborns.
In conclusion, the results obtained from the plasma
separation PalmLab blood glucose monitoring system
correlate well with those obtained from the YSI Stat Plus
system in arterial blood samples with high PO2 levels in
pediatric patients in critical care units.
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